The historical rank and industry rank for IDEAYA Biosciences's Net Margin % or its related term are showing as below:
IDYA'
s Net Margin % Range Over the Past 10 Years
Min: -3921.1 Med: -177.33 Max: -51.99
Current: -62.17
IDYA's Net Margin % is ranked better than 53.12% of 947
companies
in the Biotechnology industry
Industry Median: -89.56
vs IDYA: -62.17
IDEAYA Biosciences (NAS:IDYA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
IDEAYA Biosciences Net Margin % Related Terms
IDEAYA Biosciences Net Margin % Historical Data
* Premium members only.
The historical data trend for IDEAYA Biosciences's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, IDEAYA Biosciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEAYA Biosciences Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's Net Margin % distribution charts can be found below:
* The bar in red indicates where IDEAYA Biosciences's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEAYA Biosciences (IDYA) has a Net Margin % of -1,502.12% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on IDEAYA Biosciences and its competitors. According to the industry distribution chart, IDEAYA Biosciences ranks #444 out of 947 companies in the Biotechnology industry, placing it in the top 46.9%.
Is IDEAYA Biosciences' Net Margin % too high?
IDEAYA Biosciences' current Net Margin % is -1,502.12%. Based on the distribution chart, IDEAYA Biosciences ranks #444 out of 947 companies in the Biotechnology industry, which is above the industry midpoint. Overall, IDEAYA Biosciences has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IDEAYA Biosciences' Net Margin % compare to MLYS and TARS?
According to the Biotechnology industry distribution chart, IDEAYA Biosciences ranks #444 out of 947 companies for Net Margin %. This puts IDEAYA Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on IDEAYA Biosciences and its competitors. IDEAYA Biosciences's current Net Margin % is -1,502.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEAYA Biosciences stock overvalued right now?
Based on GuruFocus' analysis, IDEAYA Biosciences (IDYA) is currently considered Possible Value Trap. The stock's GF Value™ is $214.33, compared to a current price of $36.64 — trading 82.9% below its estimated fair value. The current Net Margin % is -1,502.12%. IDEAYA Biosciences' overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For IDEAYA Biosciences (IDYA), the current Net Margin % is -1,502.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEAYA Biosciences (IDYA) Overvalued in 2026?
Based on GuruFocus' analysis, IDEAYA Biosciences stock appears to be undervalued.
The current stock price of $36.64 is trading 82.9% below its estimated GF Value™ of $214.33.
GuruFocus considers IDEAYA Biosciences to be Possible Value Trap.
Key valuation signals for IDYA:
Net Margin %: -1,502.12%
GF Value™: $214.33 vs. price of $36.64 (82.9% below fair value)
No single metric tells the full story. See the IDYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
55GF Score
Get the complete analysis for IDYA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDYA has been successfully added to your 
